A new study shows Glivec is three times more effective than current first-line treatment for Chronic Myeloid Leukaemia (CML).
The American study compared Glivec to Interferon Combination Therapy, and found it is nearly three times more effective, and significantly delays the progression to the advanced stages of CML.
Following these results, Novartis will soon submit an application to health authorities globally for the use of Glivec as first line treatment in CML.
